XMMO Fact Sheet


Invesco S&P MidCap Momentum ETF

$130.99
close, Nov 18, 2026

Over the year to Nov 18, 2026, XMMO returned -0.3% in total and charged 0.34% a year.

1-year total return	Expense ratio	Net assets	Net flow, last 5 trading days
-0.3% to Nov 18, 2026	**0.34%** a year	**$6.1bn** on Nov 17, 2026	**-$87.0m** daily basis to Nov 17, 2026

Growth of $10,000, 1 year



XMMO **$9,967** -0.3% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.

Returns

WINDOW	TOTAL RETURN
1 month	**-6.8%**
3 months	**-17.7%**
Year to date	**-4.9%**
1 year	**-0.3%**
3 years	**+61.6%**
5 years	**+43.8%**

Total return, distributions reinvested, each window to Nov 18, 2026.

Ten largest positions

HOLDING	WEIGHT
Roivant Sciences Ltd	**4.28%**
TechnipFMC PLC	**4.16%**
ATI Inc	**4.12%**
United Therapeutics Corp	**2.72%**
Jazz Pharmaceuticals PLC	**2.69%**
MKS Inc	**2.59%**
TD SYNNEX Corp	**2.56%**
HF Sinclair Corp	**2.56%**
BrightSpring Health Services Inc	**2.42%**
Reliance Inc	**2.24%**

XMMO top ten by weight, 30.3% of the fund, of its 79 equity positions, from the holdings published by its issuer for Nov 17, 2026.

Facts

Equity fund · Tracks the S&P MidCap 400 Momentum Index · First traded Mar 3, 2005 · Benchmark Its own holdings, as of Nov 17, 2026

ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/xmmo.